Larsson Tobias, Nisbeth Ulf, Ljunggren Osten, Jüppner Harald, Jonsson Kenneth B
Department of Medical Sciences, University Hospital, Uppsala, Sweden.
Kidney Int. 2003 Dec;64(6):2272-9. doi: 10.1046/j.1523-1755.2003.00328.x.
Hyperphosphatemia is a risk factor for the development of several different complications of chronic kidney disease (CKD), including secondary hyperparathyroidism and cardiovascular complications, due to the formation of calcium-phosphate deposits. Fibroblast growth factor-23 (FGF-23) is a recently discovered protein that is mutated in autosomal-dominant hypophosphatemic rickets, an inherited phosphate wasting disorder, and it may represent a novel hormonal regulator of phosphate homeostasis. We therefore hypothesized that FGF-23 levels may be altered in hyperphosphatemia associated with renal failure and that its concentration changes in response to different levels of phosphate intake.
Using a two-site enzyme-linked immunosorbent assay (ELISA) detecting the C-terminal portion of FGF-23, serum concentration was measured in 20 patients with different stages of renal failure (creatinine range 155 to 724 micromol/L), in 33 patients with end-stage renal disease (ESRD) on dialysis treatment, and in 30 patients with functioning renal grafts. Furthermore, six healthy males were given oral phosphate binders in combination with low dietary phosphate intake for 2 days followed by 3 days of repletion with inorganic phosphate. FGF-23 levels were determined at multiple time points.
FGF-23 serum levels were significantly elevated in CKD with a strong correlation between serum creatinine and FGF-23 concentration. Independent correlations were also seen between FGF-23 and phosphate, calcium, parathyroid hormone (PTH), and 1,25(OH)2D3. No changes in serum FGF-23 levels were observed in volunteers following ingestion of oral phosphate binders/low dietary phosphate intake, which led to a decline in phosphate excretion or during the subsequent repletion with inorganic phosphate through oral phosphate and a normal diet.
Circulating FGF-23 was significantly elevated in patients with CKD and its concentration correlated with renal creatinine clearance. In healthy volunteers, FGF-23 levels did not change after phosphate deprivation or phosphate loading.
高磷血症是慢性肾脏病(CKD)多种不同并发症发生的危险因素,包括继发性甲状旁腺功能亢进和心血管并发症,这是由于磷酸钙沉积的形成。成纤维细胞生长因子23(FGF-23)是一种最近发现的蛋白质,在常染色体显性低磷性佝偻病(一种遗传性磷消耗性疾病)中发生突变,它可能代表了磷稳态的一种新型激素调节因子。因此,我们推测在与肾衰竭相关的高磷血症中FGF-23水平可能会改变,并且其浓度会随着不同水平的磷摄入而变化。
使用检测FGF-23 C末端部分的双位点酶联免疫吸附测定(ELISA),对20例不同肾衰竭阶段(肌酐范围为155至724微摩尔/升)的患者、33例接受透析治疗的终末期肾病(ESRD)患者以及30例有功能肾移植的患者测定血清浓度。此外,6名健康男性连续2天口服磷结合剂并低磷饮食,随后3天补充无机磷。在多个时间点测定FGF-23水平。
CKD患者的FGF-23血清水平显著升高,血清肌酐与FGF-23浓度之间存在强相关性。FGF-23与磷、钙、甲状旁腺激素(PTH)和1,25(OH)2D3之间也存在独立相关性。在志愿者摄入口服磷结合剂/低磷饮食导致磷排泄减少后,或随后通过口服磷和正常饮食补充无机磷期间,未观察到血清FGF-23水平的变化。
CKD患者循环中的FGF-23显著升高,其浓度与肾肌酐清除率相关。在健康志愿者中,磷缺乏或磷负荷后FGF-23水平未发生变化。